A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study

J. Kellogg Parsons; Peter A. Pinto; Christian P. Pavlovich; Edward Uchio; Hyung L. Kim; Mikel N. Nguyen; James L. Gulley; Christina Jamieson; Paul Hsu; Margarita Wojtowicz; Howard Parnes; Jeffrey Schlom; William L. Dahut; Ravi A. Madan; Renee N. Donahue; H. H.Sherry Chow

doi:10.1016/j.euf.2018.08.016

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study

J. Kellogg Parsons
, Peter A. Pinto
, Christian P. Pavlovich
, Edward Uchio
, Hyung L. Kim
, Mikel N. Nguyen
, James L. Gulley
, Christina Jamieson
, Paul Hsu
, Margarita Wojtowicz
, Howard Parnes
, Jeffrey Schlom
, William L. Dahut
, Ravi A. Madan
, Renee N. Donahue
, H. H.Sherry Chow

Research output: Contribution to journal › Comment/debate › peer-review

21 Scopus citations

Abstract

The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5 mo. Final results will be available in 2019.

Original language	English (US)
Pages (from-to)	636-638
Number of pages	3
Journal	European Urology Focus
Volume	4
Issue number	5
DOIs	https://doi.org/10.1016/j.euf.2018.08.016
State	Published - Sep 2018

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.euf.2018.08.016

Cite this

Parsons, J. K., Pinto, P. A., Pavlovich, C. P., Uchio, E., Kim, H. L., Nguyen, M. N., Gulley, J. L., Jamieson, C., Hsu, P., Wojtowicz, M., Parnes, H., Schlom, J., Dahut, W. L., Madan, R. A., Donahue, R. N., & Chow, H. H. S. (2018). A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. European Urology Focus, 4(5), 636-638. https://doi.org/10.1016/j.euf.2018.08.016

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. / Parsons, J. Kellogg; Pinto, Peter A.; Pavlovich, Christian P. et al.
In: European Urology Focus, Vol. 4, No. 5, 09.2018, p. 636-638.

Research output: Contribution to journal › Comment/debate › peer-review

Parsons, JK, Pinto, PA, Pavlovich, CP, Uchio, E, Kim, HL, Nguyen, MN, Gulley, JL, Jamieson, C, Hsu, P, Wojtowicz, M, Parnes, H, Schlom, J, Dahut, WL, Madan, RA, Donahue, RN & Chow, HHS 2018, 'A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study', European Urology Focus, vol. 4, no. 5, pp. 636-638. https://doi.org/10.1016/j.euf.2018.08.016

@article{867e2ad9d6744effa11c518dd4c66252,

title = "A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study",

abstract = "The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5 mo. Final results will be available in 2019.",

author = "Parsons, \{J. Kellogg\} and Pinto, \{Peter A.\} and Pavlovich, \{Christian P.\} and Edward Uchio and Kim, \{Hyung L.\} and Nguyen, \{Mikel N.\} and Gulley, \{James L.\} and Christina Jamieson and Paul Hsu and Margarita Wojtowicz and Howard Parnes and Jeffrey Schlom and Dahut, \{William L.\} and Madan, \{Ravi A.\} and Donahue, \{Renee N.\} and Chow, \{H. H.Sherry\}",

note = "Publisher Copyright: {\textcopyright} 2018 European Association of Urology",

year = "2018",

month = sep,

doi = "10.1016/j.euf.2018.08.016",

language = "English (US)",

volume = "4",

pages = "636--638",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier B.V.",

number = "5",

}

TY - JOUR

T1 - A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer

T2 - The Immunotherapy to Prevent Progression on Active Surveillance Study

AU - Parsons, J. Kellogg

AU - Pinto, Peter A.

AU - Pavlovich, Christian P.

AU - Uchio, Edward

AU - Kim, Hyung L.

AU - Nguyen, Mikel N.

AU - Gulley, James L.

AU - Jamieson, Christina

AU - Hsu, Paul

AU - Wojtowicz, Margarita

AU - Parnes, Howard

AU - Schlom, Jeffrey

AU - Dahut, William L.

AU - Madan, Ravi A.

AU - Donahue, Renee N.

AU - Chow, H. H.Sherry

PY - 2018/9

Y1 - 2018/9

N2 - The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5 mo. Final results will be available in 2019.

AB - The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5 mo. Final results will be available in 2019.

UR - https://www.scopus.com/pages/publications/85052933323

UR - https://www.scopus.com/pages/publications/85052933323#tab=citedBy

U2 - 10.1016/j.euf.2018.08.016

DO - 10.1016/j.euf.2018.08.016

M3 - Comment/debate

C2 - 30197041

AN - SCOPUS:85052933323

SN - 2405-4569

VL - 4

SP - 636

EP - 638

JO - European Urology Focus

JF - European Urology Focus

IS - 5

ER -

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this